Moreover, efficiency of neratinib was not inferior than other reference treatments for advanced or metastatic HER2+ BC (trastuzumab plus paclitaxel [45] or lapatinib plus capecitabine) [44]. This evidence concerns the gene ERBB2 and breast cancer.